Table 1. Baseline Patient Characteristics.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Total (N = 240) | Discovery cohort (n = 93) | Validation cohort (n = 147) | |
| Age, mean (range), y | 63.0 (56.3-68.0) | 60.8 (52.3-65.6) | 64.0 (59.0-69.0) |
| Sex | |||
| Female | 89 (37) | 39 (42) | 50 (34) |
| Male | 151 (63) | 54 (58) | 97 (66) |
| Clinical risk score | |||
| <2 | 53 (23) | 32 (37) | 21 (15) |
| ≥2 | 178 (77) | 55 (63) | 123 (85) |
| Incomplete | 9 | 6 | 3 |
| >1 Liver metastasis | 151 (64) | 39 (42) | 112 (78) |
| Node-positive primary | 151 (67) | 55 (64) | 96 (69) |
| Preoperative CEA >200 ng/mL | 12 (6) | 3 (4) | 9 (6) |
| Disease-free interval <12 mo | 157 (65) | 51 (55) | 106 (72) |
| Metastasis size >5 cm | 61 (25) | 23 (25) | 38 (26) |
| Shortest margin between cancer and cut surface | |||
| ≥1 cm | 76 (34) | 24 (28) | 52 (38) |
| <1 cm | 120 (54) | 48 (56) | 72 (53) |
| No margin (cancer visible on cut surface) | 27 (12) | 14 (16) | 13 (9) |
| Not availablea | 17 | 7 | 10 |
Abbreviation: CEA, carcinoembryonic antigen.
a
Margin distance between cancer and cut surface was designated as not available if considered not evaluable (eg, due to ablation being performed as part of hepatic resection).